News for Healthier Living

Modified Personalized Cancer Vaccine Generates Powerful Immune Response

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform. The findings are published in Cell.

July 10, 2025


July 12 2025

July 11 2025

July 10 2025

July 9 2025

July 8 2025

July 7 2025

July 6 2025

July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025

June 30 2025

June 29 2025

June 28 2025